{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:50:39Z","timestamp":1768441839388,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11596-022-2620-6","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T07:02:27Z","timestamp":1662188547000},"page":"1015-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors"],"prefix":"10.1007","volume":"42","author":[{"given":"Zi-yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-feng","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyman","family":"Makamure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gan-sheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-sheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"10127","key":"2620_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018,391(10127):1301\u20131314","journal-title":"Lancet"},{"issue":"9","key":"2620_CR2","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int, 2015,35(9):2155, 2166","journal-title":"Liver Int"},{"issue":"4","key":"2620_CR3","first-page":"438","volume":"37","author":"I Bargellini","year":"2017","unstructured":"Bargellini I, Florio F, Golfieri R, et al. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol, 2017,37(4):438\u2013444","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"2620_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","volume":"28","author":"RC Gaba","year":"2017","unstructured":"Gaba, RC, Lokken RP, Hickey RM, et al. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol, 2017,28(9):1210\u20131223.e3","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"2620_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00270-009-9762-9","volume":"33","author":"B Liang","year":"2010","unstructured":"Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Intervent Radiol, 2010,33(4):806\u2013812","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"2620_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","volume":"70","author":"JW Park","year":"2019","unstructured":"Park JW, Kim YJ, Kim, DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol, 2019,70(4):684\u2013691","journal-title":"J Hepatol"},{"issue":"6","key":"2620_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/dmd.112.050310","volume":"41","author":"J Ding","year":"2013","unstructured":"Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos, 2013,41(6):1195\u20131210","journal-title":"Drug Metab Dispos"},{"issue":"76","key":"2620_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0274-7","volume":"51","author":"Q Liang","year":"2019","unstructured":"Liang Q, Kong L, Du Y, et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. Exp Mol Med, 2019,51(76):1\u201311","journal-title":"Exp Mol Med"},{"issue":"9","key":"2620_CR9","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1002\/cam4.1664","volume":"7","author":"C Yang","year":"2018","unstructured":"Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med, 2018,7(9):4570\u20134583","journal-title":"Cancer Med"},{"issue":"3","key":"2620_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/15384047.2018.1529099","volume":"20","author":"Z Yang","year":"2019","unstructured":"Yang Z, Chen G, Cui Y, et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther, 2019,20(3):321\u2013327","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2620_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","volume":"18","author":"W Lu","year":"2017","unstructured":"Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther, 2017,18(6):433\u2013438","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2620_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1186\/s12885-018-5081-3","volume":"18","author":"S Chen","year":"2018","unstructured":"Chen S, Yu W, Zhang K. Comparison of the efficacy and safety of transarterial chemoembolization with and without apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer, 2018,18(1):1131","journal-title":"BMC Cancer"},{"issue":"2","key":"2620_CR13","first-page":"608","volume":"24","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Feng B, Mei L, et al. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON, 2019,24(2):608\u2013614","journal-title":"J BUON"},{"issue":"8","key":"2620_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.clinthera.2019.04.036","volume":"41","author":"W Fan","year":"2019","unstructured":"Fan W, Yuan G, Fan H, et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: a multicenter retrospective study. Clin Ther, 2019,41(8):1463\u20131476","journal-title":"Clin Ther"},{"issue":"10","key":"2620_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fonc.2020.00970","volume":"7","author":"X Kan","year":"2020","unstructured":"Kan X, Liang B, Zhou G, et al. Transarterial Chemoembolization Combined with Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol, 2020,7(10):970","journal-title":"Front Oncol"},{"issue":"1","key":"2620_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018,69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"3","key":"2620_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou J, Sun HC, Wang Z, et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018,7(3):235\u2013260","journal-title":"Liver Cancer"},{"key":"2620_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ. Apatinib: A Review in Advanced Gastric Cancer and Other Advance Cancers. Drugs, 2018,78:747\u2013758","journal-title":"Drugs"},{"key":"2620_CR19","unstructured":"Qiu L, Shukui Q, Shanzhi G. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: a randomized, placebo-controlled, doubleblind, phase 3 study. 2020, ASCO Annual Meeting Symposium: 303249"},{"issue":"7","key":"2620_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/cancers11070985","volume":"11","author":"VC Kok","year":"2019","unstructured":"Kok, VC, Chen Y, Chen Y, et al. Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers (Basel), 2019,11(7):985","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2620_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000489790","volume":"8","author":"SC Chien","year":"2019","unstructured":"Chien SC, Chen CY, Cheng PN, et al. Combined Transarterial Embolization\/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer, 2019,8(3):186\u2013202","journal-title":"Liver Cancer"},{"issue":"8","key":"2620_CR22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jvir.2018.03.020","volume":"29","author":"Y Sato","year":"2018","unstructured":"Sato Y, Nishiofuku H, Yasumoto T, et al. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol, 2018,29(8):1061\u20131067","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"2620_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-019-04004-z","volume":"85","author":"J Liu","year":"2020","unstructured":"Liu J, Xie S, Duan X, et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. Cancer Chemother Pharmacol, 2020,85(1):69\u201376","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2620_CR24","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/s41598-020-59746-1","volume":"10","author":"C Zhou","year":"2020","unstructured":"Zhou C, Yao Q, Zhang H, et al. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep, 2020,10(1):2964","journal-title":"Sci Rep"},{"issue":"4","key":"2620_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.acra.2017.10.018","volume":"25","author":"JY Ni","year":"2018","unstructured":"Ni JY, Kong J, Sun HL, et al. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol, 2018,25(4):423\u2013429","journal-title":"Acad Radiol"},{"issue":"59","key":"2620_CR26","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.18632\/oncotarget.20140","volume":"8","author":"C Liu","year":"2017","unstructured":"Liu C, Xing W, Si T, et al. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget, 2017,8(59):100734\u2013100735","journal-title":"Oncotarget"},{"issue":"5","key":"2620_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.acra.2019.07.003","volume":"27","author":"J Liu","year":"2019","unstructured":"Liu J, Xu J, Zhang W, et al. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. Acad. Radiol, 2019,27(5): 704\u2013709","journal-title":"Acad. Radiol"},{"issue":"3","key":"2620_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0221-7","volume":"51","author":"Z Liao","year":"2019","unstructured":"Liao Z, Li F, Zhang C, et al. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med, 2019,51(3):1\u201311","journal-title":"Exp Mol Med"},{"issue":"30","key":"2620_CR29","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","volume":"29","author":"TM Pawlik","year":"2011","unstructured":"Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol, 2011,29(30):3960\u20133967","journal-title":"J Clin Oncol"},{"issue":"2","key":"2620_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension, 2018,71(2):e1\u2013e8","journal-title":"Hypertension"},{"issue":"18","key":"2620_CR31","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","volume":"26","author":"AB Siegel","year":"2008","unstructured":"Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol, 2008,26(18):2992\u20132998","journal-title":"J Clin Oncol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-022-2620-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:24:59Z","timestamp":1666758299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-022-2620-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s11596-022-2620-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}